NCT05005403 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05005403
Title	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	AbbVie
Indications	gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer pancreatic adenocarcinoma colorectal cancer gastric adenocarcinoma ovarian serous carcinoma lung non-small cell carcinoma
Therapies	ABBV-514 + Telisotuzumab adizutecan ABBV-514 + Budigalimab ABBV-514 ABBV-514 + Bevacizumab
Age Groups:	senior \| adult
Covered Countries	USA \| ISR \| CAN

Additional content available in CKB BOOST